Cash and cash equivalents as of March 31, 2024, were approximately $42.0 million. Akebia expects its existing cash resources and cash from operations will be sufficient to fund its current operating plan, including a U.S. Vafseo launch, for at least the next two years.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKBA:
- Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Akebia Therapeutics (AKBA) Q1 Earnings Cheat Sheet
- Akebia price target raised to $6 from $5 at H.C. Wainwright
- Largest borrow rate increases among liquid names
- Akebia Therapeutics Celebrates FDA Approval of Anemia Drug
